Our Resources | Association for Accessible Medicines

GRx+Biosims - No-cost FDA workshop limited to first 100 who sign up. Act now!

Aug 26, 2019 | Erica Klinger

Giving, Volunteering and More: How Our Members Show They Care

Jul 30, 2019 | Ashlie Van Meter

A Generic Summer Savings Tour: How Did Your State Do?

Jul 29, 2019 | Maddy Murphy

Prescription Drug Safety on Campus

Jul 23, 2019 | Rachel Schwartz

AAM Applauds Senate Finance’s Meaningful Effort to Reduce Drug Prices for America’s Patients

Video

Jul 19, 2019 | Erica Klinger

AAM's Ashlee Koonce Shares New Exhibitor Opportunities at GRx+Biosims 2019

Video

Jul 19, 2019 | Erica Klinger

AAM's Christine Simmon Talks About Biosimilar Programming at GRx+Biosims 2019

Jul 11, 2019 | Jonathan Kimball

The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions

Jul 2, 2019 | Rachel Schwartz

National Survey Finds Significant Voter Opposition to Patent Settlement Legislation

Biosimilars

Jun 26, 2019 | Rachel Schwartz

AAM Applauds Sens. Cornyn and Blumenthal’s Efforts to Accelerate Access to More Affordable Biosimilar Medicines

Jun 26, 2019 | Jennifer Soup

GRx+Biosims 2019: Register Now and Be Part of the Solution

Jun 26, 2019 | Jewel Smith

AAM Announces New 2019 Members

Jun 25, 2019 | Erik Komendant

Section 205 is Still Flawed and Erodes the Only Incentive to Challenge Brand-Name Drug Patents. Here’s Why.